Search results for " CDMO"

Article CDMOs Driving Emerging Bio/Pharma Success
For that reason, CDMOs and contract research organizations (CROs) are the real enablers of success for emerging bio/pharma companies. By relying on CDMOs, emerging bio/pharma companies can get …

Article Step Up to GMP Manufacturing or Outsource to a CDMO: Considerations and Tips
Whether you are developing a new monoclonal antibody (mAb), cell therapy, gene therapy, or large-molecule biologic drug, the decision to tackle GMP manufacturing in-house or work with a contract devel…

Article Is Not Using a CDMO Slowing Down Your Process Development?
Consider what process development capabilities you have versus what you could possibly gain from working with a CDMO to not only be successful, but also to improve your chances of getting to market …

Article Contract Manufacturing Through the Years
In light of Pharmaceutical Technology’s 40th anniversary, it is appropriate to review the CDMO industry’s evolution and outlook. Early days Phase one of the CDMO industry includes the y…

Article Climate Change in Outsourcing
…and clinical supplies management are still in their early stages, and the larger analytical labs and CDMOs are positioning themselves for those opportunities. Small is beautiful. Global bio/pharm…

Article The Tide Stays High
Not surprisingly, this has been great news for CDMOs and CROs. Most publicly-traded services providers achieved revenue growth well in excess of 10% in 2016 (based on interim results), especially in t…

Article A Plastic Pipeline for Commercial Bioprocessing?
“For a CDMO whose goal is to fill the plant with products, gaining this type of changeover time is critical for them. They can sell this to their customers because they can fill their plant in an effi…

Article Good Manufacturing Practices: Challenges with Compliance
…quality, Catalent; Judy Cohen, vice-president of Quality and Regulatory at Lubrizol Life Science’s CDMO Division; and Dino Muzzin, senior vice-president of manufacturing operations at Emergent BioSol…

Article Gene Therapies Push Viral Vector Production
Vicaire states that a combination of structural evolution on the CDMO side and development of new technical solutions on equipment suppliers’ side can solve production challenges. “We must bring robus…

Article Taking a “Development-by-Design” Approach to Cell Therapies
More CDMOs are entering cell therapy market niche Demand for specialized cell therapy manufacturing and development services is also growing, and has attracted Lonza Bioservices, Cognate BioService…

Next Page